[March 04, 2014] |
|
Enanta Pharmaceuticals Announces New Data Presented on Protease Inhibitor ABT-493 at the 21st Conference on Retroviruses and Opportunistic Infections (CROI)
WATERTOWN, Mass. --(Business Wire)--
Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA) a research and
development-focused biotechnology company dedicated to creating small
molecule drugs in the infectious disease field, today announced that new in
vitro data on ABT-493, a potent NS3/4 protease inhibitor, was
presented today during a poster session at the 21st
Conference on Retroviruses and Opportunistic Infections (CROI) in Boston.
ABT-493 is a next-generation HCV NS3/4A protease inhibitor identified
within the Enanta-AbbVie collaboration. Designed to enable once-daily
dosing without ritonavir, ABT-493 is expected to be co-formulated with
AbbVie's next-generation NS5A inhibitor, ABT-530.
Data from poster number 636 titled "ABT-493, a Potent HCV NS3/4
Protease Inhibitor with Broad Genotypic Coverage", demonstrates that
ABT-493 has a substantially improved in vitro profile compared to
earlier generation HCV NS3/4A protease inhibitors and displays potent
and broad genotypic activity in genotypes 1a, 1b, 2a, 3a, 4a and 6a,
against which many other HCV NS3/4A protease inhibitors have
significantly lower potency. In vitro ABT-493 retains potency
against most of the clinically important resistance-associated variants
in genotype 1 and is fully active against variants resistant to NS5A or
NS5 inhibitors. It demonstrates additive to synergistic antiviral
activity in vitro when combined with next-generation NS5A
inhibitor ABT-530.
About Enanta
Enanta Pharmaceuticals is a research and development-focused
biotechnology company that uses its robust chemistry-driven approach and
drug discovery capabilities to create small molecule drugs in the
infectious disease field. Enanta is discovering, and in some cases
developing, novel inhibitors designed for use against the hepatitis C
virus (HCV). These inhibitors include members of the direct acting
antiviral (DAA) inhibitor classes - protease (partnered with AbbVie),
NS5A (partnered with Novartis) and nucleotide polymerase - as well as a
host-targeted antiviral (HTA) inhibitor class targeted against
cyclophilin. Additionally, Enanta has created a new class of
antibiotics, called Bicyclolides, for the treatment of multi-drug
resistant bacteria, with a focus on developing an intravenous and oral
treatment for hospital and community MRSA (methicillin-resistant Staphylococcus
aureus) infections.
Forward Looking Statement
This press release contains forward-looking statements, including with
respect to our expectation regarding how ABT-493 will be co-formulated
with ABT-530 and the prospects for ABT-493's activity against multiple
genotypes of HCV. Statements that are not historical facts are based on
our management's current expectations, estimates, forecasts and
projections about our business and the industry in which we operate and
our management's beliefs and assumptions. The statements contained in
this release are not guarantees of future performance and involve
certain risks, uncertainties and assumptions, which are difficult to
predict. Therefore, actual outcomes and results may differ materially
from what is expressed in such forward-looking statements. Important
factors that may affect actual results include results of further
preclinical and clinical studies of ABT-493-containing regimens, the
development, regulatory and marketing efforts of AbbVie (our
collaborator on ABT-493 and on our collaboration's initial protease
inhibitor, ABT-450), and clinical development and marketing efforts of
others for competitive product candidates. Enanta cautions investors not
to place undue reliance on the forward-looking statements contained in
this release. These statements speak only as of the date of this
release, and Enanta undertakes no obligation to update or revise these
statements, except as may be required by law.
[ Back To TMCnet.com's Homepage ]
|